Importantly, the knockdown of either CtBP1 or FOXM1 and targeting of the CtBP1-FOXM1 complex members with specific inhibitors, including NSM0018 and NSC95397 for CtBP1, and RCM1 for FOXM1, significantly decreased the MDR1 level and increased the chemosensitivity of osteosarcoma CSCs (Figure 10B). This evidence concerns the gene CTBP1 and osteosarcoma.